12 MONTH RESULTS OF COMPLIANCE 360: A PROSPECTIVE, MULTICENTER, RANDOMIZED TRIAL COMPARING ORBITAL ATHERECTOMY TO BALLOON ANGIOPLASTY FOR CALCIFIED FEMOROPOPLITEAL LESIONS

12 MONTH RESULTS OF COMPLIANCE 360: A PROSPECTIVE, MULTICENTER, RANDOMIZED TRIAL COMPARING ORBITAL ATHERECTOMY TO BALLOON ANGIOPLASTY FOR CALCIFIED FEMOROPOPLITEAL LESIONS

E2085 JACC March 27, 2012 Volume 59, Issue 13 Vascular Disease 12 MONTH RESULTS OF COMPLIANCE 360: A PROSPECTIVE, MULTICENTER, RANDOMIZED TRIAL COMPA...

98KB Sizes 0 Downloads 26 Views

E2085 JACC March 27, 2012 Volume 59, Issue 13

Vascular Disease 12 MONTH RESULTS OF COMPLIANCE 360: A PROSPECTIVE, MULTICENTER, RANDOMIZED TRIAL COMPARING ORBITAL ATHERECTOMY TO BALLOON ANGIOPLASTY FOR CALCIFIED FEMOROPOPLITEAL LESIONS ACC Moderated Poster Contributions McCormick Place South, Hall A Saturday, March 24, 2012, 9:30 a.m.-10:30 a.m.

Session Title: Endovascular Therapy: State of the Science I Abstract Category: 37. Endovascular Therapy Presentation Number: 1123-37 Authors: Raymond Dattilo, St. Francis Health Center, Topeka, KS, USA Background: Stent placement in the distal superficial femoral and popliteal arteries is associated with increased risk of stent fracture and restenosis. Lesion calcification is predictive of vessel dissection and recoil after PTA. This study examines whether orbital atherectomy (OA), by changing the compliance of calcified femoropopliteal (FP) lesions through the mechanism of differential sanding, diminishes the need for adjunctive stenting without sacrificing patency. This abstract reports the 12 month results. Methods: 50 symptomatic patients (65 lesions) from 9 sites with calcified FP lesions of ≥70% were equally randomized to PTA alone vs. OA followed by low pressure PTA up to 4 atm with the endpoint of residual stenosis ≤30%. Lesions failing to achieve this endpoint with the prescribed therapy were then treated with adjunctive stenting. Freedom from target lesion revascularization (TLR), including the need for adjunctive stenting, or restenosis defined as a peak systolic velocity ratio of ≥2.5 on duplex study at 6 months, was the primary endpoint. Patients are to be followed up to 24 months. Results: 92.1% of 38 lesions in the OA arm and 22.2% of 27 lesions in the PTA arm (p<0.0001) met the angiographic endpoint after primary therapy. Overall mean lesion length was 68 mm. There were significantly more diabetics in the OA arm. 2 of 25 pts in the OA arm (8%) vs. 21 of 25 pts in the PTA arm (84%) required adjunctive stenting (p<0.0001). Mean maximum balloon pressure (a measure of lesion compliance) in the OA arm was 3.9 atm vs. 9.1 atm in the PTA arm (p<0.0001). The Primary Endpoint: Freedom from TLR (including acute adjunctive stenting) or DUS restenosis at 6 months was met in 72.7% (16/22) of pts in the OA arm and 8.3% (2/24) of pts in the PTA arm (p<0.0001). By 12 months, restenosis or repeat TLR occurred in 5/21 pts in the PTA arm (4 in-stent) and 5/20 pts in the OA arm (p=NS); similar rates despite the large disparity in stent use. Conclusions: Compared to PTA alone, orbital atherectomy with low pressure PTA leads to better luminal gain by improving lesion compliance with less need for adjunctive stenting when treating calcified FP lesions. Patency at 12 months is comparable to PTA with a provisional stent strategy. .